Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1 × Zoledronic Acid × Gastrointestinal × Clear all

Phase

Phase 2 2 Phase 3 1 Phase 1 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 4 CNS 4 Plasma cell 3 Gynecologic 2 Genitourinary 2 Breast 2 Tumor-Agnostic 1 Other neoplasm 1 Other hematologic neoplasm 1 Myeloid 1 Lymphoid 1 Gastrointestinal 1

Conditions

CLDN18.2-positive Gastric Adenocarcinoma 1

Interventions

Gemcitabine 178 Fluorouracil 120 Oxaliplatin 110 Capecitabine 102 pembrolizumab 96 Irinotecan 93 Leucovorin 84 Bevacizumab 83 Cisplatin 71 Radiotherapy 68 Cetuximab 67 Nivolumab 65 130-nm albumin-bound paclitaxel 62 Sorafenib 49 Cyclophosphamide 46 Paclitaxel 44 Albumin-Bound Paclitaxel 44 Carboplatin 39 Docetaxel 35 Magnetic Resonance Spectroscopy 34 Specimen Handling 33 Erlotinib Hydrochloride 32 Radiation 31 fludarabine 30 durvalumab 27 Taxes 26 Biopsy 26 Ipilimumab 25 atezolizumab 24 IFL protocol 22

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT01671774 2024-11-14

PILOT

Astellas Pharma Inc

Phase 1 Completed

Gastrointestinal

CLDN18.2-positive Gastric Adenocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡